Home

The Ayush Journal of Integrative Oncology (AJIO) (ISSN: 1111-8888), the official publication of the All-India Institute of Ayurveda (AIIA) under the Ministry of Ayush, Government of India, is a peer-reviewed, quarterly journal (January, April, July, October) dedicated to publishing high-quality research, reviews, and case studies on integrative cancer management through the Ayush system, conventional medicine, and global traditional practices. AJIO covers diverse topics, including Ayurveda, Yoga, Unani, Siddha, Homeopathy, Tibetan medicine, biomedicine, public health, pharmacology, pharmacognosy, ethnobotany, ethnopharmacology, conservation, biotechnology, biochemistry, medicinal chemistry, novel drug delivery systems, and herbal drug quality control. The journal is indexed in leading databases such as Baidu Scholar, CNKI, EBSCO, Google Scholar, ProQuest, and Wanfang Data. AJIO explores the standalone as well as integrative benefits of traditional therapies in combination with chemotherapy, immunotherapy, hormone therapy, targeted treatments, personalized vaccines, cell therapy, microbiome treatments, mobile screening technologies, and nanotechnology, along with safety considerations. It also includes biopurificatory methods such as Panchakarma and also rehabilitation approaches. AJIO invites submissions in the form of original research articles, systematic reviews, meta-analyses, case studies, clinical observations, and reviews on phytochemicals, herbal formulations, and integrative oncology innovations. Committed to rigorous peer review, AJIO ensures enhanced visibility and a strong impact in the field of integrative oncology. With no page charges for submissions, authors can follow the Author Instructions and submit manuscripts via the AJIO Submission Portal.

AJIO Website Link:  https://journals.lww.com/ajio/pages/default.aspx

AJIO Submission Portal Link: https://review.jow.medknow.com/ajio

Instructions

​ Instructions for Authors

​The Editorial Process

A manuscript will be reviewed for possible publication with the understanding that it is being submitted to Ayush Journal of Integrative Oncology (AJIO) alone at that point in time and has not been published anywhere, simultaneously submitted, or already accepted for publication elsewhere. The journal expects that authors would authorize one of them to correspond with the Journal for all matters related to the manuscript. All manuscripts received are duly acknowledged. On submission, editors review all submitted manuscripts initially for suitability for formal review. Manuscripts with insufficient originality, serious scientific or technical flaws, or lack of a significant message are rejected before proceeding for formal peer-review. Manuscripts that are unlikely to be of interest to the AJIO readers are also liable to be rejected at this stage itself.

Manuscripts received from Editorial Board (EB) members: The journal will be following double blind peer review process for all articles. The external peer reviewers selected will not be affiliated with the institution/organization as that of the author(s).  The manuscripts submitted by the Society (i.e., WAF/TDU) and EB members are no exceptions. The Society (i.e., WAF/TDU) and EB members (including the Editor-in-Chief) are never included in any editorial or review process of their authored submissions and will be excluded from publication decisions. All Society (i.e., WAF/TDU) and EB members are expected to mention their association with the journal and declare Conflict of Interest during manuscript submission.

Manuscripts that are found suitable for publication in AJIO are sent to two or more expert reviewers. During submission, the contributor is requested to provide names of two or three qualified reviewers who have had experience in the subject of the submitted manuscript, but this is not mandatory. The reviewers should not be affiliated with the same institutes as the contributor/s. However, the selection of these reviewers is at the sole discretion of the editor. The journal follows a double-blind review process, wherein the reviewers and authors are unaware of each other’s identity. Every manuscript is also assigned to a member of the editorial team, who based on the comments from the reviewers takes a final decision on the manuscript. The comments and suggestions (acceptance/ rejection/ amendments in manuscript) received from reviewers are conveyed to the corresponding author. If required, the author is requested to provide a point-by-point response to reviewers’ comments and submit a revised version of the manuscript. This process is repeated till reviewers and editors are satisfied with the manuscript. The Editor-in-Chief will be the final decision maker after considering the comments from the editorial team. Manuscripts accepted for publication are copy edited for grammar, punctuation, print style, and format. Page proofs are sent to the corresponding author. The corresponding author is expected to return the corrected proofs within three days. It may not be possible to incorporate corrections received after that period. The whole process of submission of the manuscript to final decision and sending and receiving proofs is completed online. To achieve faster and greater dissemination of knowledge and information, the journal publishes articles online as ‘Ahead of Print’.

Processes for appeals

The authors do have the right to appeal if they have a genuine cause to believe that the editorial board has wrongly rejected the paper. If the authors wish to appeal the decision, they should email the editorial office (editor_aiia@ajio.org.in) explaining in detail the reason for the appeal. The appeals will be acknowledged by the editorial office and will be investigated in an unbiased manner. The processing of appeals will be done within 6 – 8 weeks. While under appeal, the said manuscript should not be submitted to other journals. The final decision rests with the Editor in Chief of the journal. Second appeals are not considered.

Anti-plagiarism policy

Plagiarism includes duplicate publication of the author’s own work, in whole or in part without proper citation or mispresenting other’s ideas, words, and other creative expression as one’s own. The Journal follows strict anti-plagiarism policy. All manuscripts submitted to AJIO undergoes plagiarism check with commercially available software. Based on the extent of plagiarism, authors may be asked to address any minor duplication, or similarity with the previous published work. If plagiarism is detected after publication, the Journal will investigate. If plagiarism is established, the journal will notify the authors’ institution and funding bodies and will retract the plagiarised article. To report plagiarism, contact the journal office (editor_aiia@ajio.org.in).

Clinical trial registry

Ayush Journal of Integrative Oncology favours registration of clinical trials and abides by the Statement on publishing clinical trials in Indian biomedical journals. AJIO would publish clinical trials that have been registered with a clinical trial registry that allows free online access to public. Registration in the following trial registers is acceptable:

http://www.ctri.nic.in/; https://www.anzctr.org.au/; http://www.clinicaltrials.gov/; http://isrctn.org/; http://www.trialregister.nl/trialreg/index.asp; 

http://www.umin.ac.jp/ctr. This is applicable to clinical trials that have begun enrolment of subjects in or after June 2018. Clinical trials that have commenced enrolment of subjects prior to June 2018 would be considered for publication in AJIO only if they have been registered retrospectively with clinical trial registry that allows unhindered online access to public without charging any fees.

• Clinical trials (interventional studies) only those are registered with Clinical Trials Registry- India (CTRI) http://www.ctri.nic.in will be considered for publication.
• The authors need to mention CTRI registration number in covering letter and in the article file.
• All the randomized controlled trials should be described on the basis of revised CONSORT statement, which is available at http://www.consort-statement.org.

Authorship Criteria

All those designated as authors/contributors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors.

1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Participation solely in the acquisition of funding or the collection of data does not justify authorship. General supervision of the research group is not sufficient for authorship. Each contributor should have participated sufficiently in the work to take public responsibility for appropriate portions of the content of the manuscript. The order of naming the contributors should be based on the relative contribution of the contributor towards the study and writing the manuscript. Once submitted the order cannot be changed without written consent of all the contributors. The journal prescribes a maximum number of authors for manuscripts depending upon the type of manuscript, its scope and number of institutions involved (vide infra). The authors should provide a justification, if the number of authors exceeds these limits.

Author declaration: All authors must declare their contributions to the manuscript and confirm their authorship by uploading a signed Copyright Transfer Form. All authors must also declare their conflict of interest by uploading and AJIO Conflict of Interest Form duly filled by each author. Please upload the filled, signed forms (Author Contribution Form) while submitting the manuscript on our online manuscript processing system https://review.jow.medknow.com/ajio .

Contributors who meet fewer than all 4 of the above criteria for authorship should not be listed as authors, but they should be acknowledged. The corresponding author obtain written permission to be acknowledged from all acknowledged individuals.

Contribution Details

Contributors should provide a description of contributions made by each of them towards the manuscript. Description should be divided in following categories, as applicable: concept, design, definition of intellectual content, literature search, clinical studies, experimental studies, data acquisition, data analysis, statistical analysis, manuscript preparation, manuscript editing and manuscript review. Authors’ contributions will be printed along with the article. One or more authors should take responsibility for the integrity of the work as a whole from inception to published article and should be designated as ‘guarantor’. The authors must fully declare their contributions to the manuscript. A CReDiT (Contributor Roles Taxonomy) Author Statement must be uploaded as part of the Covering Letter.

Conflicts of Interest/ Competing Interests

All authors of articles must disclose any and all conflicts of interest they may have with publication of the manuscript or an institution or product that is mentioned in the manuscript and/or is important to the outcome of the study presented. If the articles are authored by the editorial board, the conflict of interest must be clearly stated.

All authors are expected to fill the AJIO Conflict of Interest form and this form must be uploaded during manuscript submission.

Policy on pre-print

The journal accepts manuscripts that have been published on pre-print servers. However, the author(s) must declare that they have uploaded their manuscript on a pre-print server and provide its details viz., manuscript title, pre-print server name, DOI and link in the covering letter. In the event that the author(s) fails to declare the pre-print submissions and provide the necessary information, the manuscript will be rejected. The author(s) should also bear in mind that manuscripts uploaded on pre-print servers will undergo a single blind peer review process as identity of the author(s) is disclosed in a public domain. The articles published previously on pre-print servers will under-go the same editorial quality checks, peer reviews and decision-making process as any other manuscript.

Submission of Manuscripts

All manuscripts must be submitted on-line through the website https://review.jow.medknow.com/ajio. First time users will have to register at this site. Registration is free but mandatory. Registered authors can keep track of their articles after logging into the site using their username and password. Authors do not have to pay for submission, processing or publication of articles. If you experience any problems, please contact the editorial office by e-mail at (editor_aiia@ajio.org.in). The submitted manuscripts that are not as per the “Instructions to Authors” would be returned to the authors for technical correction, before they undergo editorial/ peer-review. Generally, the manuscript should be submitted in the form of two separate files:

[1] Title Page/First Page File/covering letter

This file should provide

1. The type of manuscript (original article, case report, review article, Letter to editor, Images, etc.) title of the manuscript, running title, names of all authors/ contributors (with their highest academic degrees, designation and affiliations) and name(s) of department(s) and/ or institution(s) to which the work should be credited. All information which can reveal your institute affiliation should be here. Use text/rtf/doc files. Do not zip the files.
2. The total number of pages, total number of photographs and word counts separately for abstract and for the text (excluding the references, tables and abstract), word counts for introduction + discussion in case of an original article.
3. If the manuscript was presented as part at a meeting, the organization, place, and exact date on which it was read. A full statement to the editor about all submissions and previous reports that might be regarded as redundant publication of the same or very similar work. Any such work should be referred to specifically and referenced in the new paper. Copies of such material should be included with the submitted paper, to help the editor decide how to handle the matter.
4. Registration number in case of a clinical trial and where it is registered (name of the registry and its URL).
5.  Source(s) of support in the form of grants, equipment and/or drugs. Manuscripts should include details about the funding agency/ sponsors, grant number and the role of funders. If the funders have no role to play or the study did not receive funding, a statement declaring the same should be mentioned. 
6. A statement confirming appropriate patient consent for publication has been obtained should be mentioned for case reports/ case series, and articles that include patient images.
7. Acknowledgement, if any. One or more statements should specify 1) contributions that need acknowledging but do not justify authorship, such as general support by a departmental chair; 2) acknowledgments of technical help; and 3) acknowledgments of financial and material support, which should specify the nature of the support.
8. Conflicts of Interest of each author/ contributor: All manuscripts for articles, original research reports, editorials, comments, reviews, book reviews, and letters submitted to the journal must include a conflict-of-interest disclosure statement or a declaration by the authors that they do not have any conflicts of interest to declare. A statement of financial or other relationships that might lead to a conflict of interest, if that information is not included in the manuscript itself or in an authors’ form.
9. Data Availability statement: All manuscripts should include a statement about where data supporting the results reported in a published article can be found.
10. Data sharing statement: Clinical trials must contain a data sharing statement such as whether individual deidentified participant data (including data dictionaries) will be shared (“undecided” is not an acceptable answer); what data in particular will be shared; whether additional, related documents will be available (e.g., study protocol, statistical analysis plan, etc.); when the data will become available and for how long; by what access criteria data will be shared (including with whom, for what types of analyses, and by what mechanism).
11. Clinical trials articles should include a statement about Where the full trial protocol can be accessed, if available
12. Criteria for inclusion in the authors’/ contributors’ list (CRediT taxonomy)
13. A statement that the manuscript has been read and approved by all the authors, that the requirements for authorship as stated earlier in this document have been met, and that each author believes that the manuscript represents honest work, if that information is not provided in another form (see below); and
14. The name, address, e-mail, and telephone number of the corresponding author, who is responsible for communicating with the other authors about revisions and final approval of the proofs, if that information is not included on the manuscript itself.
15. If a manuscript is submitted on behalf of a consortium or group, include its name in the manuscript byline. Do not add it to the author list in the submission system. You may include the full list of members in the Acknowledgments or in a supporting information file.

[2] Blinded Article file: The main text of the article, beginning from Abstract till References (including tables) should be in this file. The file must not contain any mention of the authors’ names or initials or the institution at which the study was done or acknowledgements. Page headers/running title can include the title but not the authors’ names. Manuscripts not in compliance with the Journal’s blinding policy will be returned to the corresponding author. Use rtf/doc files. Do not zip the files. Limit the file size to 1 MB. Do not incorporate images in the file. If file size is large, graphs can be submitted as images separately without incorporating them in the article file to reduce the size of the file. The pages should be numbered consecutively, beginning with the first page of the blinded article file. Hence, the authors must ensure that the main manuscript file does not contain author details or any details that may reveal their identity.

[3] Images: Submit good quality colour images. Each image should be less than 2 MB in size. Size of the image can be reduced by decreasing the actual height and width of the images (keep up to 1600 x 1200 pixels or 5-6 inches). Images can be submitted as jpeg files. Do not zip the files. Legends for the figures/images should be included at the end of the article file. 

[4] The copyright process is now digital to streamline manuscript submissions. Please follow these guidelines for a smooth submission process:

• The submitting author must ensure that all co-authors, with their correct email addresses [mandatory], are added in the ‘Authors and Institutions‘ section during the third step of online submission.
• After submission, all co-authors will receive an email with a link to provide their digital copyright consent. Please ensure all co-authors complete this process within seven days of submission.
• The submitting author can track the copyright status of their co-authors in the ‘Manuscript Information‘ page by clicking the manuscript ID on their dashboard.
• Do not upload scanned copies of signed copyright forms during submission.
• Manuscript review will proceed only after all co-authors have submitted their digital copyright consent.​

In the event that the article is accepted for publication, authors will transfer, assign or otherwise convey all copyright ownership, including any and all rights incidental thereto, exclusively to the Journal.

Preparation of Manuscripts

Manuscripts must be prepared in accordance with “Uniform requirements for Manuscripts submitted to Biomedical Journals” developed by the International Committee of Medical Journal Editors (Updated December 2021). The specific requirement of Ayush Journal of Integrative Oncology are summarized below. Before submitting a manuscript, contributors are requested to check for the latest instructions available. Instructions are also available from the website of the journal and from the manuscript submission site https://review.jow.medknow.com/ajio ).

Ayush Journal of Integrative Oncology accepts manuscripts written in British English.

Copies of any permission(s)

It is the responsibility of authors/ contributors to obtain permissions for reproducing any copyrighted material. A copy of the permission obtained must accompany the manuscript. Copies of any and all published articles or other manuscripts in preparation or submitted elsewhere that are related to the manuscript must also accompany the manuscript.

Types of Manuscripts

The authors are required to use the downloadable word document templates provided at the end of this page to prepare the manuscripts. The reporting guidelines checklist is provided in these templates which must be duly followed. The authors can also choose the reporting guidelines for the specific study design from the web links provided in the table below and upload it along with the manuscript.

Reporting guidelines: The authors are expected to follow relevant reporting guidelines prescribed by the EQUATOR Network. Please visit to select the appropriate reporting guideline relevant to your study type: https://www.equator-network.org/

Types of paper Contributions falling into the following categories will be considered for publication:

Editorial, Opinion Paper (Thought Leadership Article), Full Length Article (Original Research Article (Experimental), Original Research Article (Clinical), General Article, Oncology), Case Report (Case series), Short Communication, Review Article, Short Review, Discussion (Discussion Kernel, Commentary), Feature Article (Life Profiles, Vignette, Initiatives, Review of landmark articles), Correspondence (Letters), Product Review, Book Review, Practice Guidelines, and E-Publication (News and comments, Future events, Conference Report).

1. Editorials: Editorials are written by the Editorial Board member or by Guest Editors invited by the Editor-in-chief. Restrict manuscript to about 1500 words and about 15 references.
2. Opinion Papers (Thought Leadership Article): Please restrict the manuscript to about 2000 words (excluding about 20 references). Abstract is not required.
3. Original articles: These include randomized controlled trials, intervention studies, studies on screening and diagnostic test, outcome studies, cost effectiveness analyses, case-control series, and surveys with high response rate. The text of original articles amounting to up to 3000-5000 words (excluding Abstract, references and Tables) should be divided into sections with the headings Abstract, Keywords, Introduction, Material and Methods, Results, Discussion, References, Tables and Figure legends. Abstract should be structured with not more than 250 words.

Introduction: State the purpose and summarize the rationale for the study or observation.

Materials and Methods: It should include and describe the following aspects:

Original Research Article (Experimental):

1. Please restrict the structured abstract to 250 words (background, objectives, material and methods, results, conclusions) and the manuscript to about 5000 words (excluding about 70 references) and 8 non-text items. There is no authorship limit, and the only requirement is that all the authors should fulfil the ICMJE authorship criteria.
2. Experimental Research articles report authors’ original (other than clinical) research of a more technical and specialized nature. They may include studies meant for standardization of raw drugs and finished formulations, toxicity and efficacy studies, studies exploring significance of Ayurvedic pharmaceutical processes in the area of integrative oncology.
3. Studies involving integrative methods/techniques for standardization of drugs and diagnosis of diseases based on Ayurvedic classical guidelines will be appreciated.
4. Authors should mention details of authentication of raw drugs and finished formulations used, animal ethics committee clearance (if applicable) and guidelines followed for the study.
5. For all biochemical/laboratory procedures, either provide sufficient details or a reference for the relevant details. Provide name and address of the manufacturer for trade names or commercial products.
6. Please follow ARRIVE guidelines for reporting in-vivo research (https://www.nc3rs.org.uk/arrive-guidelines

Original Research Article (Clinical):

1. Clinical studies may include clinical trials, cross sectional studies, case control and cohort studies.
2. Research conducted on humans should be in compliance with the declaration of Helsinki and the principles of Good Clinical Practices wherever applicable.
3. Approval of research by relevant ethics committee is mandatory and should be mentioned wherever applicable.
4. Restrict the structured abstract to 250 words and the manuscript to about 5000 words (excluding about 70 references) and 8 non-text items.
5. Each manuscript should clearly state an objective or hypothesis; the design and methods (including the study setting and dates, patients or participants with inclusion and exclusion criteria, or data sources, and how these were selected for the study).
6. Authors should include the essential features of interventions; the outcome measures; the results of the study; a discussion section placing the results in context with the published literature and addressing study limitations; and the conclusions.
7. Authors need to mention details about authentication of raw drugs and finished formulations used, ethics committee clearance, informed consents from patients and guidelines followed for the study.
8. Provide name and address of the manufacturer for trade names or commercial products.

General Article:

1. General articles report authors’ original work of a non-clinical nature, concerning topics, either within the scope of AJIO and experimental areas, or otherwise relevant to contemporary issues in Ayurveda, traditional medicine and integrative oncology.
2. Please restrict non-structured abstract to 250 words and the manuscript to about 3000 words (excluding about 50 references) and 5 non-text items.

Oncology: Articles by experienced Ayurvedic scholars of relevance to contemporary issues in education, teaching methods and approaches are expected in this section. Articles exploring epistemology, fundamental concepts and principles of Ayurveda, Yoga, Siddha, Unani and Homeopathic medicines for its better understanding, literary studies on historical, sociological and classics influencing current healthcare scenario are appreciated. Restrict the manuscript to about 3000 words (excluding about 40 references) and 5 non-text items. An abstract is not required for an Oncology article.

Ethics: When reporting studies on human beings, indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975, as revised in 2013 (available at https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/). For prospective studies involving human participants, authors are expected to mention about approval of (regional/ national/ institutional or independent Ethics Committee or Review Board, obtaining informed consent from adult research participants and obtaining assent for children aged over 7 years participating in the trial. The age beyond which assent would be required could vary as per regional and/ or national guidelines. Ensure confidentiality of subjects by desisting from mentioning participants’ names, initials or hospital numbers, especially in illustrative material. When reporting experiments on animals, indicate whether the institution’s or a national research council’s guide for, or any national law on the care and use of laboratory animals was followed. Evidence for approval by a local Ethics Committee (for both human as well as animal studies) must be supplied by the authors on demand. Animal experimental procedures should be as humane as possible, and the details of anaesthetics and analgesics used should be clearly stated. The ethical standards of experiments must be in accordance with the guidelines provided by the CPCSEA (https://ccsea.gov.in/Auth/index.aspx)​ and World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Humans for studies involving experimental animals and human beings, respectively). The journal will not consider any paper which is ethically unacceptable. A statement on ethics committee permission and ethical practices must be included in all research articles under the ‘Materials and Methods’ section.

Study design:

Selection and Description of Participants: Describe your selection of the observational or experimental participants (patients or laboratory animals, including controls) clearly, including eligibility and exclusion criteria and a description of the source population. Technical information: Identify the methods, apparatus (give the manufacturer’s name and address in parentheses), and procedures in sufficient detail to allow other workers to reproduce the results. Give references to established methods, including statistical methods (see below); provide references and brief descriptions for methods that have been published but are not well known; describe new or substantially modified methods, give reasons for using them, and evaluate their limitations. Identify precisely all drugs and chemicals used, including generic name(s), dose(s), and route(s) of administration.

Reports of randomized clinical trials should present information on all major study elements, including the protocol, assignment of interventions (methods of randomization, concealment of allocation to treatment groups), and the method of masking (blinding), based on the CONSORT Statement (http://www.consort-statement.org).

The authors are required to use the downloadable word document templates provided at the end of this page to prepare the manuscripts. The reporting guidelines checklist is provided in these templates which must be duly followed. The authors can also choose the reporting guidelines for the specific study design from the web links provided in the table below and upload it along with the manuscript. Manuscripts with the incomplete checklist will be sent back to the authors.

The reporting guidelines for other type of studies can be found at https://www.equator-network.org/reporting-guidelines/.

Statistics:Whenever possible quantify findings and present them with appropriate indicators of measurement error or uncertainty (such as confidence intervals). Authors should report losses to observation (such as, dropouts from a clinical trial). When data are summarized in the Results section, specify the statistical methods used to analyse them. Avoid non-technical uses of technical terms in statistics, such as ‘random’ (which implies a randomizing device), ‘normal’, ‘significant’, ‘correlations’, and ‘sample’. Define statistical terms, abbreviations, and most symbols. Specify the computer software used. Use upper italics (P 0.048). For all P values include the exact value and not less than 0.05 or 0.001. Mean differences in continuous variables, proportions in categorical variables and relative risks including odds ratios and hazard ratios should be accompanied by their confidence intervals.

Results: Present your results in a logical sequence in the text, tables, and illustrations, giving the main or most important findings first. Do not repeat in the text all the data in the tables or illustrations; emphasize or summarize only important observations. Extra- or supplementary materials and technical detail can be placed in an appendix where it will be accessible but will not interrupt the flow of the text; alternatively, it can be published only in the electronic version of the journal.

When data are summarized in the Results section, give numeric results not only as derivatives (for example, percentages) but also as the absolute numbers from which the derivatives were calculated, and specify the statistical methods used to analyse them. Restrict tables and figures to those needed to explain the argument of the paper and to assess its support. Use graphs as an alternative to tables with many entries; do not duplicate data in graphs and tables. Where scientifically appropriate, analyses of the data by variables such as age and sex should be included.

Discussion: Include summary of key findings (primary outcome measures, secondary outcome measures, results as they relate to a prior hypothesis); Strengths and limitations of the study (study question, study design, data collection, analysis and interpretation); Interpretation and implications in the context of the totality of evidence (is there a systematic review to refer to, if not, could one be reasonably done here and now?, what this study adds to the available evidence, effects on patient care and health policy, possible mechanisms); Controversies raised by this study; and Future research directions (for this particular research collaboration, underlying mechanisms, clinical research). 

Do not repeat in detail data or other material given in the Introduction or the Results section. In particular, contributors should avoid making statements on economic benefits and costs unless their manuscript includes economic data and analyses. Avoid claiming priority and alluding to work that has not been completed. New hypotheses may be stated if needed, however they should be clearly labelled as such. About 30 references can be included.

1. Discussion Kernel: A short pithy article concerning some issue of wide potential interest, which requires, and is designed to stimulate, further discussion and debate will be considered in this section. Restrict manuscript to about 1500 words (excluding about 20 references), 3 non-text items. No abstract is required. Maximum four authors can be included.
2. Commentary: Commentary is generally solicited from reviewers on very important papers. The limit is 500 words with no abstract
3. Review articles

It is expected that these articles would be written by individuals who have done substantial work on the subject or are considered experts in the field. A short summary of the work done by the contributor(s) in the field of review should accompany the manuscript.

The Journal prefers systematic reviews that have been registered in PROSPERO https://www.crd.york.ac.uk/prospero/. The PROSPERO registry number should be provided in the review article under the “methodology” section.

1. Reviews may cover particular areas of Ayurveda, traditional medicine and integrative oncology of relevance to contemporary issues.
2. Review articles written by individuals who have done substantial work on a subject or by experts in the field are appreciated.
3. They should be systematic, state-of-art comprehensive reviews of the subject including author(s) own inputs.
4. A good review article may have author(s) claim / view after going through scientific literature pertaining to a specific area, reasons behind the claim / view, factual evidences discussing the claim / view and finally novel conclusions drawn after interlinking many research findings.
5. The section titles should depend upon the topic reviewed.
6. Authors submitting a review article should include a section describing the methods used for locating, selecting, extracting, and synthesizing data.
7. These methods should also be summarized in the abstract.
8. A review article should not be a mere compilation.
9. The journal expects the contributor to give post-publication updates and advances on the subject of review. The update should be brief and should be sent as a letter to editor, as and when major developments occur in the field.
10. Restrict non-structured abstract to 250 words and manuscript to about 6000 words (excluding about 80 references) and about 8 non-text items.

1. Case reports and Case series

New, interesting and rare cases should be reported. They should be unique, describing a great diagnostic or therapeutic challenge and providing a learning point for the readers. Cases with clinical significance or implications will be given priority. These communications could be of up to 1500 words ((excluding 20 references and abstract of up to 200 words) and could be supported with up to 20 references, 2 non-text items and include a non-structured abstract of up to 200 words. The following headings in the given order: Abstract (unstructured), Keywords, Introduction, Case report, Discussion, Reference, Tables and Legends in that order. Case Reports could be authored by up to four authors: Please follow CARE Statement available on http://www.care-statement.org for structuring case reports. Patient’s identity should not be revealed from the clinical photographs or imaging pictures. More information on “Protection of Patients’ Rights to Privacy” section.

Case Series:

1. Case Series are collection of cases with similar exposure and / or outcomes. Reporting more than three patients will be considered under case series.
2. The case series about application of Ayurveda, traditional medicine and integrative oncology and illustrate efficacy of an unusual application of a traditional treatment, hopefully indicating a solution to some contemporary medical problem will be considered for publication.
3. Restrict non-structured abstract to 250 words, manuscript about 3000 words (excluding about 40 references) and 4 non-text items. The headings should include Introduction, Methods (includes Ethical approval/exempt, patient consent/ exempt, study design, participants, pre-intervention patient optimization, Intervention, follow-up protocol), results (include the patient characteristics, diagnostic finings, treatment outcomes, follow-up, complications), discussion, references. Case series can be authored by maximum four authors.
4. Patient consent for publication should be included in case of clinical photographs are used.
5. Short Communication
   • Short communications may include important preliminary studies and reports.
   • Please provide non structured abstract to 250 words and restrict the manuscript to about 1,500 words (excluding about 20 references) and 2 non-text items.
   • Short communication present original and important preliminary findings that do not warrant publication as a full-length article but are still worthy of publication. The main text should be sub-divided into background, methods, results, and discussion, but should be written as concisely as possible.
   • Short communication can be authored by maximum six authors.
6. Short Review: A short review is expected up to 2000 words with 20 references and non-structured abstract up to 200 words. The main text should be sub-divided into background, methods, results, and discussion, but should be written as concisely as possible. Section Includes: Clinical findings, diagnostic tools, new technologies adopted, adverse drug reactions, treatment strategies followed. Short review should be authored by maximum six authors.
7. Feature Article

Life Profile: Life profile of a legendary personality, physician/scientist of today or from the past who has contributed to Ayurveda, traditional medicine and integrative oncology will be considered for publication. The article should be legible, to the point, balanced, without any prejudice or prepossession in mind and talking about the person to the fullest.

1. The number of words spent on personal life should be limited and the article should be more focused towards his/her contribution in the field of Ayurveda, traditional medicine and integrative oncology.
2. The article should clearly pick up the qualities of the person which made him an important personality in the field and should illustrate the important scientific/scholarly works, and contribution to philosophy or clinical practice. Use of quality reference material is expected.
3. Abstract is not required and restrict manuscript to about 2000 words (excluding about 20 references).
4. Authorship limit: Maximum 4 authors.

Vignettes: Vignettes retell incidents in the lives of great Vaidyas/scientist, which encapsulate and illustrate an important point about the philosophy, knowledge or practice of Ayurveda, a related AYUSH system, Ayurveda, traditional medicine and integrative oncology. Focused interviews are also considered. Please restrict the manuscript to about 2000 words and 2 Photographs if available for Vignettes, an abstract is not required. Authorship limit: Maximum 4 authors.

Initiatives:

1. Initiatives recount the history, philosophy, mission and activities of some important projects, institutions, organizations and associations making contributions to advance Ayurveda, traditional medicine and integrative oncology, medicine healthcare, either locally or globally.
2. Restrict the manuscript to about 3000 words (excluding about 30 references). Abstract is not required.
3. Illustrative pictures and diagrams will be appreciated. Initiatives articles are solicited.
4. The article may include points like focal theme of the initiative, planning and preparations done before implementation.
5. Problems faced during establishment of the initiative and how they were solved, current situation, on-going projects / programs.
6. Current problems if any, importance of the project / organization to Ayurveda, traditional medicine and integrative oncology, contribution and response of Ayurveda and Biomedicine fraternities.
7. Future plans and directions, expectations from government authorities or stakeholders, appeal for feedback (if any) and important links.
8. Authorship limit: Maximum 4 authors.

Review of Landmark Article:

1. Review of Landmark Articles gives deep insights into a scientific paper representing a turning point in the history of any aspect of Ayurveda, traditional medicine and integrative oncology.
2. Articles will be solicited or commissioned.
3. Please restrict non-structured abstract to 250 words and manuscript up to 3000 words (excluding about 50 references) with 5 non-text items.
4. Authorship limit: Maximum 4 authors.
5. Letter to the Editor:

These should be short and decisive observations. They should preferably be related to articles previously published in the Journal or views expressed in the journal. They should not be preliminary observations that need a later paper for validation. The letter could have up to 500 words and 5 references. Abstract is not required. It should be authored by not more than four authors.

Correspondence: Letters

1. Letters are welcome from all readers on topics and issues pertaining to articles in recent editions of AJIO, or to the worlds mainly of Ayurveda, other AYUSH systems and traditional medicine or Integrative Oncology.
2. Letters should be brief, concise and to the point. Restrict manuscript to about 1000 words (excluding about 15 references) and 1 non-text items.
3. Abstract is not required.
4. Authorship limit: Maximum 4 authors.
5. Others:

Product review:

1. Product review includes brief and evidence-based information about any product, devise, instrument or tools useful in clinical practice, research or translation.
2. Restrict the manuscript up to 500 words with maximum two non-text items. No abstract is required.
3. Authorship limit: Maximum 4 authors.

Book reviews:

1. Book reviews can be solicited or commissioned by AJIO editorial staff.
2. Readers are welcome to suggest high quality contemporary or historically important books on Ayurveda, traditional medicine and integrative oncology for review.
3. Offers to review such books will also be considered.
4. For unsolicited book reviews, the reviewer needs to upload a permission letter from the authors of the book.
5. Please note that in both the cases (solicited or unsolicited book review) publisher / author(s) / reviewer(s) need to send a copy of the book reviewed.
6. The reviewer should highlight who the expected readers are, introduce readers to the book’s content (but avoid repeating its table of contents), focus on the subject, its approach and novelty; inform readers about what is happening in the area which the book addresses; what is the state of knowledge in the subject; and how this new book adds, changes or breaks new ground in our knowledge of this subject.
7. If the book is an edited collection of essays, or chapters by different individuals, give some idea of the overall theme and content, but be free to focus on specific chapters you consider particularly significant or worthwhile.
8. A book review may include an introduction to the author(s), including the author’s title and place of work and some information stating who the author is, a summary of the intended purpose of the book and its contributions to Ayurveda, traditional medicine and integrative oncology.
9. A description of the way the author approaches his or her topic; the rigor of research and scholarship; the logic of the argument and the readability of the prose. If possible, a comparison with earlier or similar books in the field, and an evaluation of the book’s merits, usefulness, and special contributions may be included.
10. Abstract is not required and restrict the manuscript to about 2000 words and a jpeg image of the cover page of the book reviewed should be uploaded separately.

Practice Guidelines: Guidelines about clinical practice, research and education about Ayurveda, traditional medicine and integrative oncology will be published in this section. Please follow expected guidance for developers of reporting guidelines, available on (http://www.equator-network.org/ (AGREE/ RIGHT reporting guidelines)

Editorial, Guest Editorial, Commentary and Opinion are solicited by the editorial board.

Following article types will be published as E-publication only.

• Conference Report: Please restrict manuscript up to 1200 words with maximum two non-text items.
• News and comments: These are written by AJIO editorial staff. Readers may suggest topics and events for publication pertaining recent activities in the field of Ayurveda, traditional medicine and integrative oncology.
• Future events: 

These are generally written by AJIO editorial board members. Please submit requests for particular events to be covered. In this case, suggestions for the person to write the report will also be welcome. Authors may use the equator network site for sourcing these guidelines http://www.equatornetwork.org .

Please ensure that you select the appropriate article type from the list of options when making your submission. Authors contributing to special issues should ensure that they select the special issue article type from this list.

References

References should be numbered consecutively in the order in which they are first mentioned in the text (not in alphabetic order). Identify references in text, tables, and legends by Arabic numerals in superscript with square bracket after the punctuation marks. References cited only in tables or figure legends should be numbered in accordance with the sequence established by the first identification in the text of the particular table or figure. Use the style of the examples below, which are based on the formats used by the NLM. in Index Medicus. The titles of journals should be abbreviated according to the style used in Index Medicus. Use complete name of the journal for non-indexed journals. Avoid using abstracts as references. Information from manuscripts submitted but not accepted should be cited in the text as “unpublished observations” with written permission from the source. Avoid citing a “personal communication” unless it provides essential information not available from a public source, in which case the name of the person and date of communication should be cited in parentheses in the text. 

The commonly cited types of references are shown here, for other types of references such as newspaper items please refer to ICMJE Guidelines (http://www.icmje.org or http://www.nlm.nih.gov/bsd/uniform_requirements.html). All references must be uploaded separately and not as part of the main manuscript file.

Articles in Journals

1. Standard journal article (for up to six authors): Parija S C, Ravinder PT, Shariff M. Detection of hydatid antigen in the fluid samples from hydatid cysts by co-agglutination. Trans. R.Soc. Trop. Med. Hyg.1996; 90:255–256.
2. Standard journal article (for more than six authors): List the first six contributors followed by et al.  

Roddy P, Goiri J, Flevaud L, Palma PP, Morote S, Lima N. et al., Field Evaluation of a Rapid Immunochromatographic Assay for Detection of Trypanosoma cruzi Infection by Use of Whole Blood. J. Clin. Microbiol. 2008; 46: 2022-2027.

1. Volume with supplement: Otranto D, Capelli G, Genchi C: Changing distribution patterns of canine vector borne diseases in Italy: leishmaniosis vs. dirofilariosis.Parasites & Vectors 2009; Suppl 1:S2.  

Books and Other Monographs

1. Personal author(s): Parija SC. Textbook of Medical Parasitology. 3rd ed. All India Publishers and Distributors. 2008.
2. Editor(s), compiler(s) as author: Garcia LS, Filarial Nematodes In: Garcia LS (editor) Diagnostic Medical Parasitology ASM press Washington DC 2007: pp 319-356.
3. Chapter in a book: Nesheim M C. Ascariasis and human nutrition. In Ascariasis and its prevention and control, D. W. T. Crompton, M. C. Nesbemi, and Z. S. Pawlowski (eds.). Taylor and Francis,London, U.K.1989, pp. 87–100.

Electronic Sources as reference

Journal article on the Internet: Parija SC, Khairnar K. Detection of excretory Entamoeba histolytica DNA in the urine, and detection of E. histolytica DNA and lectin antigen in the liver abscess pus for the diagnosis of amoebic liver abscess BMC Microbiology 2007, 7: 41.doi:10.1186/1471-2180-7-41. http://www.biomedcentral.com/1471-2180/7/41

Tables

• Tables should be self-explanatory and should not duplicate textual material.
• Tables with more than 10 columns and 25 rows are not acceptable.
• Number tables, in Arabic numerals, consecutively in the order of their first citation in the text and supply a brief title for each.
• Place explanatory matter in footnotes, not in the heading.
• Explain in footnotes all non-standard abbreviations that are used in each table.
• Obtain permission for all fully borrowed, adapted, and modified tables and provide a credit line in the footnote.
• For footnotes use the following symbols, in this sequence: *, †, ‡, §, ||,¶ , **, ††, ‡‡
• Tables with their legends should be provided at the end of the text after the references. The tables along with their number should be cited at the relevant place in the text

Illustrations (Figures)

• Upload the images in JPEG format. The file size should be within 1024 kb in size while uploading.
• Figures should be numbered consecutively according to the order in which they have been first cited in the text.
• Labels, numbers, and symbols should be clear and of uniform size. The lettering for figures should be large enough to be legible after reduction to fit the width of a printed column.
• Symbols, arrows, or letters used in photomicrographs should contrast with the background and should be marked neatly with transfer type or by tissue overlay and not by pen.
• Titles and detailed explanations belong in the legends for illustrations not on the illustrations themselves.
• When graphs, scatter-grams or histograms are submitted the numerical data on which they are based should also be supplied.
• The photographs and figures should be trimmed to remove all the unwanted areas.
• If photographs of individuals are used, their pictures must be accompanied by written permission to use the photograph.
• If a figure has been published elsewhere, acknowledge the original source and submit written permission from the copyright holder to reproduce the material. A credit line should appear in the legend for such figures.
• Legends for illustrations: Type or print out legends (maximum 40 words, excluding the credit line) for illustrations using double spacing, with Arabic numerals corresponding to the illustrations. When symbols, arrows, numbers, or letters are used to identify parts of the illustrations, identify and explain each one in the legend. Explain the internal scale (magnification) and identify the method of staining in photomicrographs.
• Final figures for print production: Send sharp, glossy, un-mounted, colour photographic prints, with height of 4 inches and width of 6 inches at the time of submitting the revised manuscript. Print outs of digital photographs are not acceptable. If digital images are the only source of images, ensure that the image has minimum resolution of 300 dpi or 1800 x 1600 pixels in TIFF format. Send the images on a CD. Each figure should have a label pasted (avoid use of liquid gum for pasting) on its back indicating the number of the figure, the running title, top of the figure and the legends of the figure. Do not write the contributor/s’ name/s. Do not write on the back of figures, scratch, or mark them by using paper clips.
• The Journal reserves the right to crop, rotate, reduce, or enlarge the photographs to an acceptable size. 

List of Abbreviations: Include a list of abbreviations along with its description used in the manuscript.

Protection of Patients’ Rights to Privacy

Identifying information (such as patient name, hospital name, patient identification IDs, date of birth) should not be published in written descriptions, photographs, sonograms, CT scans, etc., and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian, wherever applicable) gives informed consent for publication. Authors should remove patients’ names from figures even if they have obtained informed consent from the patients in order to protect patient privacy. The journal abides by ICMJE guidelines:

1. Authors, not the journals nor the publisher, need to obtain the patient consent form before the publication and have the form properly archived. The consent forms are not to be uploaded with the cover letter or sent through email to editorial or publisher offices. However, they should be made available on request.
2. If the manuscript contains patient images that preclude anonymity, or a description that has obvious indication to the identity of the patient, a statement about obtaining informed patient consent should be indicated in the manuscript.
3. In order to protect the patient’s identity, the recognizable facial features not related to the study should be digitally blurred. Masking the eye region in photographs of patients is inadequate protection of anonymity and is not acceptable.
4. Written informed consent is the preferred method for obtaining consent. If verbal consent is obtained, the authors must ensure that the verbal consent is recorded in the medical case record of the patient and duly signed by witness. 

Sending a revised manuscript

The revised version of the manuscript should be submitted online in a manner similar to that used for submission of the manuscript for the first time. However, there is no need to submit the “First Page” or “Covering Letter” file while submitting a revised version. When submitting a revised manuscript, contributors are requested to include, the ‘referees’ remarks along with point-to-point clarification at the beginning in the revised file itself. In addition, they are expected to mark the changes as underlined or coloured text in the article.

Reprints and proofs

Journal provides no free printed reprints. Authors can purchase reprints, payment for which should be done at the time of submitting the proofs.

Publication schedule

The journal publishes articles on its website with a quarterly frequency.

Manuscript submission, processing and publication charges

Journal does not charge the authors or authors’ institutions for the submission, processing and/or publications of manuscripts.

Copyrights

The entire contents of the Ayush Journal of Integrative Oncology are protected under Indian and international copyrights. The Journal, however, grants to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, perform and display the work publicly and to make and distribute derivative works in any digital medium for any reasonable non-commercial purpose, subject to proper attribution of authorship and ownership of the rights. The journal also grants the right to make small numbers of printed copies for their personal non-commercial use under Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International Public License.

Checklist

Covering letter

• Signed by all contributors
• Previous publication / presentations mentioned
• Source of funding mentioned
• Conflicts of interest disclosed

Authors

• Last name and given name provided along with Middle name initials (where applicable)
• Author for correspondence, with e-mail address provided
• Number of contributors restricted as per the instructions
• Identity not revealed in paper except title page (e.g. name of the institute in Methods, citing previous study as ‘our study’, names on figure labels, name of institute in photographs, etc.)

Presentation and format

• Double spacing
• Margins 2.5 cm from all four sides
• Page numbers included at bottom
• Title page contains all the desired information
• Running title provided (not more than 50 characters)
• Abstract page contains the full title of the manuscript
• Abstract provided (according to the requirements mentioned under each article type)
• Key words
• Introduction
• Headings in title case (not ALL CAPITALS)
• The references cited in the text should be after punctuation marks, in superscript with square bracket.
• References according to the journal’s instructions, punctuation marks checked
• Send the article file without ‘Track Changes’

Language and grammar

• British English
• Write the full term for each abbreviation at its first use in the title, abstract, keywords and text separately unless it is a standard unit of measure. Numerals from 1 to 10 spelt out
• Numerals at the beginning of the sentence spelt out
• Check the manuscript for spelling, grammar and punctuation errors
• If a brand name is cited, supply the manufacturer’s name and address (city and state/country).
• Species names should be in italics

Tables and figures

• No repetition of data in tables and graphs and in text
• Actual numbers from which graphs drawn, provided
• Figures necessary and of good quality (colour)
• Table and figure numbers in Arabic letters (not Roman)
• Figure legends provided (not more than 40 words)
• Patients’ privacy maintained (patient consent required)
• Credit notes for borrowed figures/tables provided
• Write the full term for each abbreviation used in the table as a footnote

For more information visit: https://journals.lww.com/ajio/Pages/Instructions-for-Authors.aspx

Editorial Board

S.No	Designation of Panel	Name and Affiliation of Panel
1.	Editor-In-Chief	Prof. Manjusha Rajgopala Director, All India Institute of Ayurveda, New Delhi, India
2.	Associate Editors	Dr. Vitthal. G. Huddar Additional Professor, Dept. of Kayachikkitsa, All India Institute of Ayurveda (AIIA), New Delhi, India
3.		Dr. Galib R Additional Professor, Dept. of RSBK, All India Institute of Ayurveda (AIIA), New Delhi, India
4.		Dr. Shivani Ghildiyal Associate Professor, Dept. of Dravyaguna, All India Institute of Ayurveda (AIIA), New Delhi, India
5.		Dr. Richa Tripathi Scientist, All India Institute of Ayurveda (AIIA), New Delhi, India
6.	Editorial Board Members	Prof. Bhushan Patwardhan Chairman, Executive Committee, National Assessment and Accreditation Council (NAAC), Bengaluru, India
7.		Dr. M Srinivas Director, All India Institute of Medical Sciences (AIIMS), New Delhi, India
8.		Prof. Sushma Bhatnagar Head, Institute Rotary Cancer Hospital (IRCH), Jhajjar, New Delhi, India.
9.		Dr. Shalini Singh Director, Indian Council of Medical Research-National Institute of Cancer Prevention & Research (ICMR-NICPR), Noida, Uttar Pradesh, India
10.		Prof. S.K. Sarin Director, Institute of Liver and Biliary Sciences (ILBS), New Delhi, India
11.		Dr. Denis Chang Director, NICM Health Research Institute, Western Sydney University, Australia.
12.		Dr. Christian S Kessler Research Coordinator, Charitie Medical University, Berlin, Germany.
13.		Mrs. Adriane Mocker Noaves Director, Madhava Ayurveda Yoga, Florianopolis, Brazil
14.		Dr. Jean Claude Zenklusen Director, The Cancer Genome Atlas (TCGA), National Cancer Institute (NCI), National Institutes of Health (NIH), USA.
15.		Dr. Wui-Jin Koh Senior Vice President, National Comprehensive Cancer Network (NCCN), USA.
16.		Prof. P K Prajapati Vice Chancellor, Dr. Sarvepalli Radhakrishnan Rajasthan Ayurveda University & Head, Deptt. of RSBK, All India Institute of Ayurveda (AIIΑ), New Delhi, India
17.		Prof. Anand More Dean PG Studies & Head, Deptt. of Roga Nidana & Vikriti Vigyan, All India Institute of Ayurveda (AIIA), New Delhi, India
18.		Prof. Mahesh Vyas Dean PhD Studies & Head, Deptt. of Maulika Siddhanta, All India Institute of Ayurveda (AIIA), New Delhi, India
19.		Prof. B. J. Patgiri I/C Director, Institute of Teaching and Research in Ayurveda, (TTRA), Jamnagar, Gujarat, India
20.		Prof. Sanjeev Sharma Vice Chancellor, National Institute of Ayurveda (NIA), Jaipur, Rajasthan, India
21.		Dr. Manoj Nesari I/C Director, North Eastern Institute of Ayurveda and Homoeopathy (NEIAH), Shillong, Meghalaya, India
22.		Prof. Rabinarayan Acharya Director General, Central Council for Research in Ayurveda Sciences (CCRAS), New Delhi, India
23.		Dr. N. J. Muthukumar Director General, Central Council for Research in Siddha (CCRS), Chennai, Tamil Nadu, India.
24.		Dr. Raghvendra Rao M Director, Central Council for Research in Yoga & Naturopathy (CCRYN), New Delhi, India.
25.		Dr. N. Zaheer Ahmed Director General, Central Council for Research in Unani Medicine (CCRUM), New Delhi, India
26.		Dr. Subhash Kaushik Director General, Central Council for Research in Homeopathy (CCRH), New Delhi, India.
27.		Prof. (Dr). GK Rath Former, Head, National Cancer Institute (NCI), All India Institute of Medical Sciences (AIIMS), New Delhi, India.
28.		Prof. Ravi Mehrotra Founder, Centre for Health Innovation and Policy (CHIP), Foundation Gautam Buddha Nagar, UP, India.
29.		Prof. Anurag Srivastava Former HOD, Surgery, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
30.		Prof. Maqsood Siddiqui Former Director/Chairman, Cancer Foundation of India, Chittaranjan National Cancer Institute (CNCI) Kolkata, India.
31.		Dr. Prabhudas Patel Former Professor & Head Cancer Biology Department, The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India.
32.		Dr. Vasudevan Nampoothiri Former Director, Ayurveda Medical Education, Kerala, India.
33.		Dr. Sameer Jamadagni Ayurveda Specialist, Shree Vishwamrut Avurvedic Chikitsalay & Panchakarma Kendra, Pune, Maharashtra, India.
34.		Dr. Julia T. Arnold Programs Director, Translational Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, (NCI), Bethesda, Maryland, USA.
35.		Dr. Tamura Tomohiro Director General, Department of Life Science and Biotechnology, National Institute, of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan.
36.		Dr. Sadanand Sardeshmukh Consulting Ayurvedic Physician Integrated Cancer Treatment and Research Centre (ICTRC), Wagholi, Pune, Maharashtra, India
37.		Dr. C D Sahadevan Medical Officer, Sivam Hospital Kaithamakku Thiruvananthapuram, Kerala, India.
38.		Vaidya Balendu Prakash Founder Director, VCP Cancer Research Foundation Uttarakhand, India.
39.		Dr. Yogesh Bendale Consulting Physician, Department of Oncology (Ayurveda), Rasayu Cancer Clinic, Pune, Maharashtra, India.
40.		Dr. Dilip Ghosh Director Nutriconnect, NICM Health Research Institute, Western Sydney University, Australia
41.		Dr. Vineeta Deshmukh Deputy Director, Integrated Cancer Treatment and Research Centre (ICTRC), Drug Standardization Laboratory, Bhasma Section, Atharva Nature Healthcare Pvt. Ltd. Wagholi, Pune, India.
42.		Prof. Gopikrishna Maddikera Professor & HOD, Rasashastra and Bhaishajya Kalpana, Shri Jagadguru Gavisiddheshwar, Ayurvedic Modical College and PG. Research Center, Sri Gavimath Campus, Banikatti, Koppal, Karnataka, India
43.		Dr. Rajagopala S Head, Deptt. of Kaumarabhritya, All India Institute of Ayurveda (AHA), New Delhi, India.
44.		Prof. Manjusha R Head, Deptt. of Shalakya Tantra, All India Institute of Ayurveda (AIIA), New Delhi, India.
45.		Prof. Jonah Sandrepogu Head, Deptt. of Kayachikitsa, All India Institute of Ayurveda (AIIA), New Delhi, India.
46.		Prof. Yogesh Badwe Head, Deptt of Shalya Tantra, All India Institute of Ayurveda (AIA), New Delhi, India.
47.		Prof. Anandaraman P V Head, Deptt. of Panchakarma, All India Institute of Ayurveda (AΠΑ), New Delhi, India.
48.		Dr. Meera K. Bhojani Head, Deptt. of Shareera Kriya, All India Institute of Ayurveda (ΑΠΑ), New Delhi, India.
49.		Prof. Tanuja Manoj Nesari Head, Deptt. of Dravyaguna, All India Institute of Ayurveda (ΑΠΑ), New Delhi, India.
50.		Dr. Pankaj Wanjarkhedkar Ayurveda & Integrative Cancer Consultant, Department of Oncology, Deenanath Mangeshkar Hospital & Research Center, Pune, Maharashtra, India.
51.		Dr. Manohar Gundeti Research Officer (Ayu), Clinical Department, RRAP Central Ayurveda Research Institute, RA Podar College, Worli, Mumbai, India.
52.		Dr. Showket Hussain Scientist D, Division of Molecular Oncology & Head Molecular Diagnostics, Indian Council of Medical Research-National Institute of Cancer Prevention and Research (ICMR-NICPR), Noida, UP, India

Current Issue

Previous Issues: https://journals.lww.com/ajio/pages/issuelist.aspx

Current Issues: https://journals.lww.com/ajio/pages/currenttoc.aspx

Archives

Ayush Journal of Integrative Oncology.

Please Visit: https://journals.lww.com/ajio/pages/default.aspx

Submission Link: https://review.jow.medknow.com/ajio

Contact Us

Journal Office

Ayush Journal of Integrative Oncology (AJIO),

All India Institute of Ayurveda (AIIA),

Mathura Road, Gautam Puri,

Sarita Vihar, New Delhi-110076,

Phone: 011-26950401/402

Website: www.aiia.gov.in